Bristol Myers Squibb (BMY) EBITDA Margin Growth (5y) (2014 - 2026)

Bristol Myers Squibb (BMY) EBITDA Margin Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 373.00
Dec 31, 2025 12,932.00
Sep 30, 2025 2,067.00
Jun 30, 2025 2,021.00
Mar 31, 2025 5,706.00
Dec 31, 2024 3,544.00
Sep 30, 2024 1,742.00
Jun 30, 2024 1,643.00
Mar 31, 2024 -10,178.00
Dec 31, 2023 1,484.00
Sep 30, 2023 938.00
Jun 30, 2023 3,772.00
Mar 31, 2023 1,543.00
Dec 31, 2022 3,044.00
Sep 30, 2022 2,320.00
Jun 30, 2022 1,927.00
Mar 31, 2022 -269.00
Dec 31, 2021 2,720.00
Sep 30, 2021 895.00
Jun 30, 2021 84.00